Literature DB >> 26826056

Resection of recurrent neck cancer with carotid artery replacement.

Giulio Illuminati1, Fabrice Schneider2, Antonio Minni3, Francesco G Calio4, Giulia Pizzardi4, Jean-Baptiste Ricco2.   

Abstract

OBJECTIVE: The management of patients with recurrent neck cancer invading the carotid artery is controversial. The purpose of this study was to evaluate overall survival rate, primary patency of vascular reconstructions, and quality-adjusted life-years (QALYs) after en bloc resection of the carotid artery and tumor with in-line polytetrafluoroethylene (PTFE) carotid grafting, followed by radiotherapy.
METHODS: From 2000 to 2014, 31 consecutive patients with recurrent neck cancer invading the carotid artery underwent en bloc resection and simultaneous carotid artery reconstruction with a PTFE graft, which was associated in 18 cases with a myocutaneous flap. The primary tumor was a squamous cell carcinoma of the larynx in 17 patients and of the hypopharynx in 7, an undifferentiated carcinoma of unknown origin in 4, and an anaplastic carcinoma of the thyroid in 3. All of the patients underwent postoperative radiotherapy (50-70 Gy), and 10 of them also underwent chemotherapy (doxorubicin and cisplatin).
RESULTS: None of the patients died or sustained a stroke during the first 30 days after the index procedure. Postoperative morbidity consisted of 6 transitory dysphagias, 3 vocal cord palsies, 2 wound dehiscences, 1 transitory mandibular claudication, and 1 partial myocutaneous flap necrosis. No graft infection occurred during follow-up. Fifteen patients (48%) died from metastatic cancer during a mean follow-up of 45.4 months (range, 8-175 months). None of the patients showed evidence of local recurrence, stroke, or thrombosis of the carotid reconstruction. The 5-year survival rate was 49 ± 10%. The overall number of QALYs was 3.12 (95% confidence interval, 1.87-4.37) with a significant difference between patients without metastasis at the time of redo surgery (n = 26; QALYs, 3.74) and those with metastasis (n = 5; QALYs, 0.56; P = .005). QALYs were also significantly improved in patients with cancer of the larynx (n = 17; QALYs, 4.69) compared to patients presenting with other types of tumors (n = 14; QALYs, 1.29; P = .032).
CONCLUSIONS: Aggressive en bloc resection of recurrent neck cancer with PTFE grafting can be curative in patients without metastases at the time of redo surgery. In this subset of patients, extensive neck surgery with carotid artery replacement can lead to excellent local control of the disease with improved quality of survival.
Copyright © 2016 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26826056     DOI: 10.1016/j.jvs.2015.10.098

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  4 in total

1.  Resection and reconstruction of the carotid artery for head and neck squamous cell carcinoma: a GETTEC study.

Authors:  Yonjae Kim; Pierre Philouze; Olivier Malard; Xavier Dufour; Lara Nokovitch; Philippe Céruse; Philippe Zrounba; Charles Maquet; Sophie Deneuve
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-03-31       Impact factor: 3.236

2.  Malignant meningioma with jugular vein invasion and carotid artery extension: A case report and review of the literature.

Authors:  Hui-Ying Chen; Feng Zhao; Jiang-Yuan Qin; Hai-Mei Lin; Ji-Ping Su
Journal:  World J Clin Cases       Date:  2020-12-06       Impact factor: 1.337

3.  Radiotherapy inhibits neointimal hyperplasia after artificial vascular replacement through Skp2/P27kip1.

Authors:  Jian Qiu; Chang Shu; Shuang Li; Qinggen Xiong; Lunchang Wang; Zhongtao Liu; Xin Li; Weichang Zhang
Journal:  J Radiat Res       Date:  2022-01-20       Impact factor: 2.724

4.  Opportunities and Limits in Salvage Surgery in Persistent or Recurrent Head and Neck Squamous Cell Carcinoma.

Authors:  Gerhard Frank Huber
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.